NASDAQ$CRNX
Crinetics Pharmaceuticals Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Crinetics reported financial results for the third quarter ended September 30, 2024.
Crinetics Pharmaceuticals reported its Q3 2024 financial results, highlighting the submission of the NDA for paltusotine and a strengthened balance sheet with a $575 million public offering. The company's focus remains on advancing its pipeline and preparing for the potential launch of paltusotine in 2025.
- Submitted New Drug Application (NDA) for paltusotine for the treatment of acromegaly.
- Strengthened balance sheet with $575 million public offering.
- Selected development candidate in TSH antagonist program.
- Data from CRN09682, the first drug candidate from novel Nonpeptide Drug Conjugate (NDC) platform to be presented at the North American Neuroendocrine Tumor Society (NANETS).
Headline financials
Revenue & EPS history
Crinetics · Revenue · Quarterly
$0
Revenue by segment
Crinetics · $1.1M total across 1 segment · Q4 2021
- Collaboration and license$1.1M—100.0%
Forward guidance
Crinetics anticipates additional data from the Phase 2 study of atumelnant in CAH by early 2025 and expects to finalize a Phase 3 protocol and initiate site startup activities for paltusotine in carcinoid syndrome by the end of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
+1.1%
Avg return
Earnings day
+1.4%
Avg return
5 days after
-1.0%
Avg return
30 days after
45%
14 / 31 earnings
Positive
+14.8%
Q2 2020
Best reaction
-13.0%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.3% | -11.5% | -21.1% | |
| Q4 2025 | -6.1% | -9.7% | -23.0% | |
| Q3 2025 | -8.0% | -1.5% | +7.3% | |
| Q1 2025 | -6.2% | -4.3% | +0.9% | |
| Q4 2024 | +7.7% | +2.2% | +4.6% | |
| Q3 2024 | -1.8% | -8.8% | -7.3% | |
| Q2 2024 | -1.4% | +4.2% | +4.3% | |
| Q1 2024 | -5.7% | -3.0% | -12.1% | |
| Q4 2023 | +1.2% | +7.5% | +15.7% | |
| Q3 2023 | -6.7% | -11.7% | +9.8% | |
| Q2 2023 | -7.3% | -8.3% | -10.2% | |
| Q1 2023 | +3.6% | +9.4% | +2.0% | |
| Q4 2022 | +2.2% | -0.3% | -17.6% | |
| Q3 2022 | -0.8% | -3.0% | -11.4% | |
| Q2 2022 | +8.6% | +4.3% | +2.1% | |
| Q1 2022 | +11.2% | +26.2% | +10.3% | |
| Q4 2021 | +11.6% | +25.3% | +3.3% | |
| Q3 2021 | +0.7% | -0.8% | -10.7% | |
| Q2 2021 | +13.3% | +31.9% | +40.8% | |
| Q1 2021 | -0.7% | -3.2% | -0.8% | |
| Q4 2020 | -0.7% | +4.0% | +15.4% | |
| Q3 2020 | -7.8% | -1.2% | -2.6% | |
| Q2 2020 | +14.8% | +3.4% | -5.3% | |
| Q1 2020 | +14.3% | +14.8% | -5.8% | |
| Q4 2019 | -13.0% | -33.2% | -33.1% | |
| Q3 2019 | -0.4% | -3.6% | +13.3% | |
| Q2 2019 | -4.5% | -0.6% | -8.1% | |
| Q1 2019 | -2.3% | +0.8% | -12.8% | |
| Q4 2018 | +8.1% | +8.1% | -0.3% | |
| Q3 2018 | +8.8% | +8.5% | +27.9% | |
| Q2 2018 | -2.9% | -2.5% | -7.2% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro